Welcome to our dedicated page for Haemonetics news (Ticker: HAE), a resource for investors and traders seeking the latest updates and insights on Haemonetics stock.
Haemonetics Corporation reports recurring developments across its global medical technology business, including financial results, investor conference participation, product studies and U.S. regulatory actions. The company’s solutions include hospital technologies, end-to-end plasma collection technologies for plasma centers and products used by blood centers to collect blood components.
Company news frequently centers on the VASCADE MVP and VASCADE MVP XL venous vascular closure systems, the NexSys PCS Plasma Collection System and Persona technology. Updates also cover FDA approvals or 510(k) clearances, clinical evidence supporting device use, earnings releases and presentations, and communications tied to the company’s plasma, blood center and hospital markets.
Haemonetics (NYSE: HAE) has announced the availability of its third quarter fiscal year 2025 financial results for the period ended December 28, 2024, on its Investor Relations website. The company will host a conference call and webcast with investors and analysts on February 6, 2025, at 8:00 a.m. ET to discuss the results.
Participants can access the teleconference through registration and will receive a dial-in number with a personalized PIN. A live webcast is also available on Haemonetics' investor relations website. The company has posted the earnings release that will be referenced during the call on their website. A replay of the conference call and webcast will be accessible for one year starting February 6, 2025, at 11:00 a.m. ET.
Haemonetics (NYSE: HAE) has completed the sale of its whole blood assets to GVS, S.p.A for a total consideration of up to $67.8 million. The deal includes $45.3 million upfront payment and potential earn-outs of up to $22.5 million over four years.
The transaction encompasses Haemonetics' whole blood collection, processing and filtration solutions portfolio, along with its Covina, California manufacturing facility and related assets in Tijuana, Mexico. The company plans to use the proceeds for general corporate purposes and growth initiatives.
Haemonetics will maintain its Blood Center business, continuing to manufacture and provide apheresis solutions for automated blood collection, including devices and disposable kits for platelets, plasma, and red cells collection.
Haemonetics (NYSE: HAE) has announced it will release its third quarter fiscal year 2025 financial results on Thursday, February 6, 2025 at 6:00 am ET. The company will host a conference call with investors and analysts at 8:00 am ET on the same day to discuss the results and address questions.
Participants can access the call via teleconference after completing registration, and are encouraged to join 10 minutes before the start. A live webcast will be available on Haemonetics' investor relations website, with both the conference call and webcast replay accessible for one year starting February 6, 2025, at 11:00 am ET.
Haemonetics (NYSE: HAE) has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco. Chris Simon, President and CEO, is scheduled to present on Tuesday, January 14, 2025, at 5:15 pm Pacific Time.
The presentation will be accessible to the public through a live audio webcast via the conference platform and through Haemonetics' Investor Relations website under the Events & Presentations section. A replay of the presentation will remain available for 30 days following the event, accessible through both platforms approximately one hour after the live presentation concludes.
Haemonetics (NYSE: HAE) has announced the sale of its whole blood assets to GVS, S.p.A for up to $67.1M, including $44.6M upfront and potential earn-outs of $22.5M over four years. The deal includes Haemonetics' whole blood collection, processing and filtration solutions, along with manufacturing facilities in Covina, California and related assets in Tijuana, Mexico. The transaction is expected to close in Q1 2025.
Haemonetics will continue its Blood Center business, manufacturing apheresis solutions for automated blood collection. This move aligns with the company's strategy to focus on commercial and non-commercial plasma leadership and expand in high-growth hospital markets.
Haemonetics (NYSE: HAE) announced the availability of its second quarter fiscal year 2025 financial results, ended September 28, 2024, on its Investor Relations website. The company will host a conference call and webcast with investors and analysts on November 7, 2024, at 8:00 a.m. ET to discuss the results. Participants are recommended to join 10 minutes before the event starts. A replay of the conference call and webcast will be available for one year starting November 7, 2024, at 11:00 a.m. ET.
Haemonetics (NYSE: HAE) has announced its plans to release second quarter fiscal year 2025 financial results on Thursday, November 7, 2024, at 6:00 am ET. The company will host a conference call with investors and analysts at 8:00 am ET on the same day to discuss the results and answer questions. Interested parties can access the call via teleconference or through a live webcast on Haemonetics' investor relations website. Registration is required for the teleconference, and participants are advised to join 10 minutes before the event start. A replay of the conference call and webcast will be available for one year starting from November 7, 2024, at 11:00 am ET.
Haemonetics (NYSE: HAE) has announced the full market release of its VASCADE MVP® XL mid-bore venous closure system in the United States. This new addition to the VASCADE® portfolio features:
- 58% more collagen and a larger disc than the VASCADE MVP® system
- Designed for procedures requiring 10-12F sheaths (up to 15F in outer diameter)
- Suitable for cryoablation, Pulsed Field Ablation (PFA), and Left Atrial Appendage Closure (LAAC)
The system has been available in a market release since June 2024, used by approximately 80 physicians at over 30 hospitals. Haemonetics aims to expand indications for larger access points through ongoing clinical trials.
Haemonetics (NYSE: HAE) has announced the availability of its first quarter fiscal year 2025 financial results on its Investor Relations website. The company will host a conference call and webcast on August 8, 2024, at 8:00 a.m. ET to discuss the results with investors and analysts. Participants can access the call via a teleconference link or a live webcast. The earnings release referenced during the call is also available on the company's website. A replay of the conference call and webcast will be accessible for one year starting from August 8, 2024, at 11:00 a.m. ET.
Haemonetics (NYSE: HAE) has announced CE Mark certification and the first commercial European procedures for its SavvyWire® Pre-Shaped Pressure Guidewire. This innovative device is the world's first 3-in-1 solution for Transcatheter Aortic Valve Implantation (TAVI), offering improved procedural efficiency through predictable wire performance, hemodynamic measurement, and left-ventricular pacing capabilities.
The certification allows Haemonetics to enter EU markets and other regions recognizing CE marking. The first commercial European procedures were performed in France and The Netherlands. The SavvyWire guidewire reduces procedural device exchanges, provides stable aortic valve delivery, and enables continuous cardiac hemodynamic monitoring. It also allows for reliable LV pacing without additional devices or venous access.